Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
480 participants
OBSERVATIONAL
2023-07-18
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Prediction of Postpartum Glucose Metabolism Abnormalities in Gestational Diabetes Mellitus
NCT05670548
Biomarkers for Early Screening of Gestational Diabetes Mellitus
NCT05142020
The Study of Biomarker in Early Diagnosis of GDM by Metabolomics
NCT05733195
Early Diagnosis of GDM by Multiomics
NCT05386927
Serum Biomarkers Associated With Postpartum T2DM in Women With GDM
NCT04539288
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GDM group
Pregnant women aged 20-40 with positive oral glucose tolerance test (OGTT) results at 24-28 weeks.
Specimen samples and baseline data collection
The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
non-GDM group
Pregnant women aged 20-40 with negative OGTT results at 24-28 weeks.
Specimen samples and baseline data collection
The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
Control group
Healthy non-pregnant women aged 20-40.
Specimen samples and baseline data collection
The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Specimen samples and baseline data collection
The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
Specimen samples and baseline data collection
The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
Specimen samples and baseline data collection
The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No history of diabetes
* No particular dietary habits
* No previous history of other mental illnesses
* No history of drug abuse or allergies
* No history of smoking or drinking
Exclusion Criteria
* Critical illnesses such as cardiovascular disease or abnormal liver/kidney function
* Personal history of syphilis, HIV positive, and other infectious diseases
* Artificial insemination or IVF pregnancy
* Multiple pregnancy (twins or more)
* Patients participating in other clinical studies
* Other reasons that researchers think are inappropriate
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Women's Hospital School Of Medicine Zhejiang University
OTHER
Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lu LI
Research Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Women's Hospital School Of Medicine Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
HU Xiaoli
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-20230193-R
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.